The clinical protocol for the Phase 2 study in pediatric MVID patients has received regulatory clearances from the U.S. Food and Drug Administration (FDA) and the EMA, and the trial will be conducted ...
Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS") China on December 16th. The ...